MTOS Technology is actively seeking strategic partnerships for technology transfer
MTOS-II is a new drug for extensively drug-resistant and multidrug-resistant tuberculosis (XDR/MDR-TB).
✔ Good safety profile and significant therapeutic effect
✔ Can be used for the clinical treatment of MDR/XDR-TB in the active phase
✔ Can be used for latent TB infection (LTBI) and for prevention to control the epidemic
Pharmacodynamic tests conducted with guinea pigs in a P3 laboratory showed that MTOS-II alone achieved significant efficacy in treating MDR/XDR-TB.
When combined with WHO-recommended drugs, it significantly improved efficacy.
The clinical dosage for human use has been screened out, demonstrating strong potential for safe and effective treatment.